109173 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
OLIGOMERS HAVING BICYCLIC SCAFFOLD MOIETIES
#302OLIGONUCLEOTIDES TARGETING XBP1
#303COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
#304Targeting enhancer RNAs for the treatment of primary brain tumors
#305UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
#306Polynucleotides containing a morpholino linker
#307CLOSED LINEAR DNA WITH MODIFIED NUCLEOTIDES
#308BRIDGED NUCLEOSIDE AND NUCLEOTIDE
#309Modulators of PCSK9 Expression
#310COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME
#311Oligonucleotides for inducing paternal UBE3A expression
#312ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#313Compositions and methods of treating facioscapulohumeral muscular dystrophy
#314Oligonucleotide Agonists Targeting Progranulin
#315Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#316Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#317ANTISENSE OLIGONUCLEOTIDE INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE
#318COMBINATORIAL INHIBITION OF TRANSCRIPTION FACTORS FOR TREATMENT OF HEART FAILURE
#319THERAPEUTICS FOR SYNGAP HAPLOINSUFFICIENCY
#320Modulators of APOL1 expression
#321COMBINATORIAL INHIBITION OF MIRNAS FOR TREATMENT OF HEART FAILURE
#322Compositions of matter for detection assays
#323TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF GENE TRANSCRIPTS
#324COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
#325RNA EDITING INHIBITORS AND METHODS OF USE
#326Guanosine Analogues for Use in Therapeutics Polynucleotides
#327METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#328ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT
#329DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR TREATING COVID-19 CONTAINING SAME
#330MODULATORS OF FOXP3 EXPRESSION
#331CYTOTOXIC T-LYMPHOCYTE BINDING APTAMERS
#332BISPECIFIC PERSONALIZED APTAMERS
#333OLIGONUCLEOTIDES FOR SPLICE MODULATION OF CARD9
#334USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#335Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#336PD-1-specific antisense oligonucleotide and its use in therapy
#337PRODUCTS FOR SUPPRESSING OR REDUCING THE EXPRESSION OR ACTIVITY OF A SNORNA AND USES THEREOF IN THE TREATMENT OF CANCER
#338Modified double-stranded RNA agents
#339Compositions and Methods for Genome Editing
#340Methods and Compositions for the ADAR-Mediated Editing of ABCA4
#341Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#342ENGINEERED NUCLEIC ACIDS AND USES THEREOF
#343CHANNEL MODULATORS
#344BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF
#345ANTISENSE OLIGONUCLEOTIDE OF CALM2
#346COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#347SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof
#348EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST
#349ANTISENSE OLIGONUCLEOTIDE OF ATN1
#350MIRNA-485 INHIBITOR FOR GENE UPREGULATION
#351USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#352Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#353COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#354USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#355Oligomeric compounds for reducing DMPK expression
#356Selective Antisense Compounds and Uses Thereof
#357Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#358Compositions for Modulating C9ORF72 Expression
#359MODIFIED DOUBLE-STRANDED RNA AGENTS
#360Compositions for treatment of polycystic kidney disease
#361PRODRUG INCORPORATED sgRNA SYNTHESIS
#362COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES
#363ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS
#364Compositions of matter for detection assays
#365ANTISENSE OLIGONUCLEOTIDE TARGETING LINC00518 FOR TREATING MELANOMA
#366PRODUCTS AND COMPOSITIONS
#367Methods and compositions for reducing pathogenic isoforms
#368Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
#369Modified compounds and uses thereof
#370STABLE TARGET-EDITING GUIDE RNA HAVING CHEMICALLY MODIFIED NUCLEIC ACID INTRODUCED THEREINTO
#371INHIBITION OF DENND5B EXPRESSION FOR TREATING HEPATIC STEATOSIS
#372Antisense Oligonucleotides Targeting ATXN3
#373MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
#374COMPOSITIONS AND METHODS FOR MODULATING ATAXIN 3 EXPRESSION
#375Tunable Reversir™ compounds
#376Methods for reactivating genes on the inactive X chromosome
#377COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS
#378EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS
#379IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME
#380Selective antisense compounds and uses thereof
#381OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#382RNA MOLECULE, CHIMERIC NA MOLECULE, DOUBLE-STRANDED RNA MOLECULE, AND DOUBLE-STRANDED CHIMERIC NA MOLECULE
#383METHODS FOR DETECTING AN ANALYTE USING STRUCTURE SWITCHING BINDING AGENTS
#384Modulation of Angiopoietin-Like 3 Expression
#385Oligonucleotide Progranulin Agonists
#386Selective reduction of allelic variants
#387RNA Interactome of Polycomb Repressive Complex 1 (PRC1)
#388Modified double-stranded RNA agents
#389AGENTS FOR THE TREATMENT OF PATIENTS WITH NSCLC AND METHODS TO PREDICT RESPONSE
#390Modified antisense oligonucleotide for inhibition of FoxP3 expression
#391Dynamic pharmacokinetic-modifying anchors
#392Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
#393ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
#3945`S-LNA nucleotides and oligonucleotides
#395COMPOSITION FOR DIAGNOSIS OR TREATMENT OF A CONDITION ASSOCIATED WITH INCREASED ACTIVITY OF EIF4E COMPRISING AN EIF4E INHIBITOR
#396METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES
#397ANTI-MIRNAS FOR THE TREATMENT OF LEIOMYOMA
#398Nucleic acids for inhibiting expression of TMPRSS6 and iron chelators
#399NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#400COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY
#401DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
#402DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF
#403METHOD OF DETECTION OF FIBRIN CLOTS
#404Compounds and methods for modulating ATXN1
#405COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
#406COMPOSITIONS AND METHODS FOR DETECTING AND TREATING INSULIN RESISTANCE
#407COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING
#408COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#409CLOSED LOOP CONTINUOUS APTAMER DEVELOPMENT SYSTEM
#410COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME
#411UBE3A ANTISENSE THERAPEUTICS
#412COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#413REVERSIR™ compounds
#414Enhanced oligonucleotides for inhibiting RTEL1 expression
#415Methods and compositions for inhibiting PMP22 expression
#416ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF
#417Modulators of Complement Factor B
#418TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS
#419COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#420Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
#421LINKED TARGET CAPTURE
#422OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE
#423COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
#424PD-L1 antisense oligonucleotides for use in tumor treatment
#425METHODS AND COMPOSITIONS OF SHORT SMALL HAIRPIN RNAS AND MICRORNAS FOR WOUND HEALING
#426ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#427METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#428Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy
#429Oral delivery of antisense conjugates targeting PCSK9
#430Antisense oligonucleotide for targeting progranulin
#431Compositions and Methods for Inhibiting Cancers and Viruses
#432HYBRIDIZING all-LNA OLIGONUCLEOTIDES
#433TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#434RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#435Compositions for modulating Ataxin 2 expression
#436OLIGONUCLEOTIDES AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
#437Novel Process for Preparing Rhenium Chelated MAG3 Oligonucleotides
#438INTRACELLULAR TARGETING OF MOLECULES
#439Modified short interfering nucleic acid (siNA) molecules and uses thereof
#440Oligonucleotides for modulating Tau expression
#441Antisense Oligonucleotides Targeting ATXN3
#442DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES WITH SHORTENED SENSE STRANDS
#443ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
#444Modulation of prekallikrein (PKK) expression
#445ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
#446NUCLEIC ACID COMPLEX FOR MODULATING IHH EXPRESSION
#447Compound for treatment of heart failure
#448ANTISENSE NUCLEIC ACID TARGETING PCSK9
#449ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#450Oligonucleotides for inducing paternal UBE3A expression
#451TARGETS AND METHODS FOR TREATING EPSTEIN-BARR VIRUS MEDIATED NEURODEGENERATION
#452ENZYMATIC RNA SYNTHESIS
#453TAU ANTISENSE OLIGOMERS AND USES THEREOF
#454TARGETING MICRORNAS TO OVERCOME DRUG TOLERANCE AND RESISTANCE
#455OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
#456METHODS AND MATERIALS FOR ACTIVATING AN INTERNAL RIBOSOME ENTRY SITE IN EXON 5 OF THE DMD GENE
#457REVERSIR TM COMPOUNDS
#458Polycomb-associated Non-Coding RNAs
#459NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL
#460MICRO RNA INTERACTIONS AS THERAPEUTIC TARGETS FOR COVID-19 AND OTHER VIRAL INFECTIONS
#461ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#4625'-Cyclo-Phosphonate Modified Nucleotides
#463PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES
#464NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE
#465METHODS FOR CONTROLLING SEIZURES BY MANIPULATING THE LEVELS OF MICRORNA-211 (miR-211) IN THE BRAIN
#466OLIGONUCLEOTIDE
#467MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#468Methods for Oral Delivery of Oligonucleotides
#469Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19
#470Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
#471Bicyclic nucleosides and oligomers prepared therefrom
#472METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS
#473Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat
#474ARTIFICIAL NUCLEIC ACIDS FOR RNA EDITING
#475METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#476MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#477DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES CONTAINING A TRILOOP
#478MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#479COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERS
#480HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE
#481Modified double-stranded RNA agents
#482METABOLIC BENEFITS OF SHORT MIR-22 MIRNA ANTAGOMIR THERAPIES
#483RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)
#484METHODS AND COMPOSITIONS FOR INHIBITION OF CRISPR RE-CLEAVAGE EVENTS
#485Modulating the cellular stress response
#486CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
#487MODULATORS OF IRF5 EXPRESSION
#488Purification methods for guanine-rich oligonucleotides
#489ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#490Compositions and their uses directed to huntingtin
#491ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9
#492Compositions and methods for treatment of cardiac diseases
#493Oligonucleotides targeting RNA binding protein sites
#494SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#495METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY
#496L-OLIGONUCLEOTIDE INHIBITORS OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2)
#497Antisense oligomers targeting PCSK9
#498METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#499BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
#500Compounds and methods for reducing prion expression
#501CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#502Compositions and methods for treatment of Friedreich's Ataxia
#503ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
#504MODIFIED DOUBLE-STRANDED RNA AGENTS
#505OLIGONUCLEOTIDE-MEDIATED SENSE CODON REASSIGNMENT
#506TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF
#507Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#508ENZYMATIC NUCLEIC ACID MOLECULES
#509COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#510OLIGONUCLEOTIDE FORMULATION METHOD
#511Oligonucleotide agonists targeting progranulin
#512RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE
#513Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
#514Methods and Compositions for the ADAR-Mediated Editing of SERPINA1
#515The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
#516OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
#517Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#518Soluble TNF Receptors and Their Use in Treatment of Disease
#519CARGO LOADED EXTRACELLULAR VESICLES
#520IN VITRO TOXICITY SCREENING ASSAY
#521GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#522Allele specific modulators of P23H rhodopsin
#523Methods for reducing LRRK2 expression
#524CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#525Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof
#526POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#527ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#528COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#529Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#530COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITIS
#531Oligonucleotides targeting frataxin and related methods
#532Small cell lung cancer therapeutic agent containing oligonucleotide
#533CHEMICALLY-MODIFIED GUIDE RNAS TO IMPROVE CRISPR-CAS PROTEIN SPECIFICITY
#534MICRORNA-134 BIOMARKER
#535METHODS AND COMPOSITIONS FOR TARGETING PD-L1
#536Artificial exosome composition and related methods
#537TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
#538ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1
#539Modified compounds and uses thereof
#540Oligonucleotide comprising an inosine for treating DMD
#541Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
#542Oligonucleotides for modulating SCN9A expression
#543Oligonucleotide Conjugates
#544Compositions and methods for improving strand biased
#545Selective antisense compounds and uses thereof
#546OLIGONUCLEOTIDES FOR CONTROLLING TAU SPLICING, AND USES THEREOF
#547Compositions for Modulating C9ORF72 Expression
#548LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#549POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
#550METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME
#551LNA BASED NANODEVICE
#552COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS
#553COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#554Compositions and methods for treating pancreatitis
#555COMPOSITIONS AND METHODS FOR NEXT GENERATION SEQUENCING
#556Compositions and methods for modulating growth hormone receptor expression
#557Combination treatment for cystic fibrosis
#558Closed loop continuous aptamer development system
#559Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#560MODULATORS OF ENaC EXPRESSION
#561Compound for treatment of heart failure
#562Nucleic acid-polypeptide compositions and uses thereof
#563bZIP transcription factors regulate conversion of nicotine to nornicotine
#564COMPOSITIONS AND METHODS FOR TARGETING GLYPICAN-2 IN THE TREATMENT OF CANCER
#565Antisense nucleic acid targeting PCSK9
#566Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes
#567Antisense-induced exon exclusion in type VII collagen
#568Modulators of EZH2 expression
#569MICRORNA TARGETING AGENT FOR TREATMENT OF HEART DISEASE
#570MiRNAs for treatment and in vitro diagnosis of drug resistant tumors
#571OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#572REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
#573Aptamers for targeted activation of T cell-mediated immunity
#574Selective Antisense Compounds and Uses Thereof
#575Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#576Oligonucleotides for reduction of PD-L1 expression
#577COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
#578Cancer chemoprevention with STAT3 blockers
#579Treatment of Fuchs' endothelial corneal dystrophy
#580Ischemic-lesion-site-specific gene therapy
#581COMPOSITIONS AND METHODS
#582Oligonucleotides for modulating Tau expression
#583POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#584CHANNEL MODULATORS
#585Thiophosphoramidites
#586RNA nanoparticles for brain tumor treatment
#587MicroRNA Compounds and Methods for Modulating MIR-122
#588RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#589Compositions and methods for modulating MECP2 expression
#590Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
#591ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1
#592OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION
#593OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
#594OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION
#595Modified Guide RNAs for Gene Editing
#596Therapeutic oligonucleotides
#597Compositions and methods for modulating apolipoprotein (a) expression
#598Modulation of alpha synuclein expression
#599Modulation of frataxin expression
#600Modulators of APOL1 expression